CA-102N is under clinical development by Holy Stone Healthcare and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CA-102N’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CA-102N overview
CA-102N is under development for the treatment of solid tumors including colorectal cancer. It is a carrier-mediated drug delivery product where hyaluronic acid is conjugated to Nimuselide-NH2.It is administered as an intravenous infusion solution. It is developed as Hyaluronic Acid Conjugated Drug (HACD). It acts by targeting CD44.
Holy Stone Healthcare overview
Holy Stone Healthcare is a Taiwan-based company principally engaged in the manufacture and wholesale of medical equipment. The Company’s main products include latent tuberculosis infection test reagents, Ostenil branded joint cavity injection and o
For a complete picture of CA-102N’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
